Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Colonic Neoplasms 1Carcinoma in Situ 1

Interventions

Docetaxel 33Prednisone 28enzalutamide 19Abiraterone Acetate 13pembrolizumab 11gallium 68 PSMA-11 9Leuprolide 9Radiotherapy 8Pluvicto 8Magnetic Resonance Spectroscopy 8Nivolumab 7Estramustine 7abiraterone 6Radiotherapy, Intensity-Modulated 6Goserelin 6Carboplatin 6Biopsy 6olaparib 5cemiplimab 5bicalutamide 5Specimen Handling 5Paclitaxel 5Cyclophosphamide 5temsirolimus 4orteronel 4darolutamide 4cabazitaxel 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Sirolimus 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prostatic Neoplasms × Indomethacin × Clear all
NCT02935205 2023-11-29

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 1/2 Unknown
38 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡